HomeCompareCSSEQ vs PFE

CSSEQ vs PFE: Dividend Comparison 2026

CSSEQ yields 593750.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSSEQ wins by $5.101516792878817e+32M in total portfolio value
10 years
CSSEQ
CSSEQ
● Live price
593750.00%
Share price
$0.00
Annual div
$0.59
5Y div CAGR
-6.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.101516792878817e+32M
Annual income
$509,806,422,165,500,040,000,000,000,000,000,000,000.00
Full CSSEQ calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — CSSEQ vs PFE

📍 CSSEQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSSEQPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSSEQ + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSSEQ pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSSEQ
Annual income on $10K today (after 15% tax)
$50,468,750.00/yr
After 10yr DRIP, annual income (after tax)
$433,335,458,840,675,000,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, CSSEQ beats the other by $433,335,458,840,675,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSSEQ + PFE for your $10,000?

CSSEQ: 50%PFE: 50%
100% PFE50/50100% CSSEQ
Portfolio after 10yr
$2.5507583964394087e+32M
Annual income
$254,903,211,082,750,020,000,000,000,000,000,000,000.00/yr
Blended yield
99.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CSSEQ
No analyst data
Altman Z
-4.1
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSSEQ buys
0
PFE buys
0
No recent congressional trades found for CSSEQ or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSSEQPFE
Forward yield593750.00%6.20%
Annual dividend / share$0.59$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-6.9%13.2%
Portfolio after 10y$5.101516792878817e+32M$51.1K
Annual income after 10y$509,806,422,165,500,040,000,000,000,000,000,000,000.00$27,210.54
Total dividends collected$5.101290799359629e+32M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CSSEQ vs PFE ($10,000, DRIP)

YearCSSEQ PortfolioCSSEQ Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$55,288,825$55,278,125.00$9,161$701.38+$55.28MCSSEQ
2$265,982,566,657$265,923,407,614.10$8,610$859.79+$265982.56MCSSEQ
3$1,113,395,109,670,623$1,113,110,508,324,299.60$8,366$1,081.25+$1113395109.66MCSSEQ
4$4,055,346,091,489,266,000$4,054,154,758,721,919,000.00$8,483$1,405.66+$4055346091489.26MCSSEQ
5$12,852,614,722,681,964,000,000$12,848,275,502,364,070,000,000.00$9,084$1,907.24+$12852614722681964.00MCSSEQ
6$35,444,009,835,467,190,000,000,000$35,430,257,537,713,930,000,000,000.00$10,418$2,732.78+$35444009835467190272.00MCSSEQ
7$85,052,144,550,231,750,000,000,000,000$85,014,219,459,707,800,000,000,000,000.00$13,007$4,193.56+$8.505214455023175e+22MCSSEQ
8$177,591,634,355,635,000,000,000,000,000,000$177,500,628,560,966,250,000,000,000,000,000.00$18,010$7,005.87+$1.7759163435563502e+26MCSSEQ
9$322,670,207,833,382,200,000,000,000,000,000,000$322,480,184,784,621,660,000,000,000,000,000,000.00$28,216$12,979.89+$3.226702078333822e+29MCSSEQ
10$510,151,679,287,881,750,000,000,000,000,000,000,000$509,806,422,165,500,040,000,000,000,000,000,000,000.00$51,081$27,210.54+$5.101516792878817e+32MCSSEQ

CSSEQ vs PFE: Complete Analysis 2026

CSSEQStock

Chicken Soup for the Soul Entertainment, Inc. operates as an advertising-supported video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Redbox, Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Popcornflix Comedy, FrightPix, Truli, and Españolflix, as well as Pivotshare, subscription VOD platform. The company also operates Redbox Free Live TV, a free ad-supported streaming television (FAST) service with various channels as well as a transactional video-on-demand (TVOD) service; and a network of kiosks for DVD rentals. In addition, it is involved in the creation, acquisition, and distribution of films and TV series; and licensing of content through theatrical, home video, pay-per-view, free, cable and pay television, and subscription and advertising video-on-demand platforms. The company was incorporated in 2016 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. operates as a subsidiary of Chicken Soup for the Soul, LLC. On June 28, 2024, Chicken Soup for the Soul Entertainment, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on July 10, 2024.

Full CSSEQ Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CSSEQ vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSSEQ vs SCHDCSSEQ vs JEPICSSEQ vs OCSSEQ vs KOCSSEQ vs MAINCSSEQ vs JNJCSSEQ vs MRKCSSEQ vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.